ACM
AVDL

ACT Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

ACT Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,500
Closed -$72K – 84
2022
Q1 		$72K Hold
10,500
– – 0.08% 72
2021
Q4 		$85K Hold
10,500
– – 0.06% 81
2021
Q3 		$103K Hold
10,500
– – 0.05% 93
2021
Q2 		$71K Buy
+10,500
New +$83.4K 0.04% 102

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

ACT Capital Management's AVDL Position: Q2 2022 in Review

ACT Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 10,500 shares — an estimated $72K sold.

ACT Capital Management first reported a position in AVDL in Q2 2021 and held it in 4 quarters. The position peaked at $103K in Q3 2021. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • ACT Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • ACT Capital Management sold 10,500 Avadel Pharmaceuticals shares in Q2 2022, an estimated $72K.
  • ACT Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • ACT Capital Management's Avadel Pharmaceuticals position peaked at $103K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on ACT Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.